Pancreatic cancer treatment device company OncoSil Medical (ASX:OSL) has announced the first treatment utilising the OncoSil device on a patient residing in Turkey.
This treatment was administered this week at the Istanbul Memorial Hospital.
OncoSil Medical CEO and managing director Nigel Lange said, “We are delighted to see the delivery of another milestone in our strategy to penetrate the large and potentially lucrative European market.
“The just completed treatment at Istanbul Memorial Hospital represents a further expansion in the geographic footprint for our revolutionary OncoSil device.
“This achievement would not have been possible without the assistance of our recently appointed Turkish distributor, EDH Nuclear Medicine & Healthcare Services. Less than three months after coming on board, they have helped us deliver the first treatment on a Turkish-domiciled patient utilising the OncoSil device.”
Istanbul Memorial Hospital Nuclear Medicine Physician Professor Cuneyt Turkmen added, “We are thrilled to be part of the OncoSil device’s ongoing validation and early commercialisation strategies.
“Given the current poor prognosis for long-term survival for patients with locally advanced pancreatic cancer, it will truly be an exciting development if the OncoSil device proves to be a more effective treatment option for patients with this type of cancer.”
